广济药业(000952) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥115,290,588.81, a decrease of 13.49% compared to ¥133,271,899.34 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥44,038,541.85, representing a decline of 627.02% from a profit of ¥8,356,171.56 in the previous year[5] - Basic earnings per share were -¥0.1244, down 611.93% from ¥0.0243 in the previous year[5] - Total operating revenue for Q1 2023 was CNY 115,290,588.81, a decrease of 13.5% compared to CNY 133,271,899.34 in Q1 2022[25] - Operating profit for Q1 2023 was a loss of CNY 45,298,268.91, compared to a profit of CNY 8,728,468.35 in Q1 2022[25] - The total profit for Q1 2023 was a loss of ¥45,818,121.92, compared to a profit of ¥7,709,901.39 in the same period last year[26] - The net profit for Q1 2023 was a loss of ¥45,398,332.51, while the previous year reported a net profit of ¥7,655,581.24[26] - The total comprehensive income for Q1 2023 was a loss of ¥45,395,595.80, while the previous year reported a comprehensive income of ¥7,647,988.93[26] Cash Flow - The net cash flow from operating activities was -¥63,018,293.69, a significant decrease of 19,051.47% compared to -¥329,051.98 in the same period last year[11] - The cash flow from operating activities showed a net outflow of ¥63,018,293.69, compared to a minor outflow of ¥329,051.98 in the previous year[29] - Cash inflow from sales of goods and services was ¥144,688,065.30, down from ¥153,321,440.76 in the same period last year[28] - The company reported a cash and cash equivalents balance of ¥389,386,320.35 at the end of Q1 2023, down from ¥428,782,094.47 at the beginning of the period[30] - The company incurred total cash outflows from investing activities of ¥32,887,188.75, compared to ¥56,998,496.47 in the previous year[29] - The financing activities generated a net cash inflow of ¥56,711,572.15, down from ¥162,240,812.11 in the same period last year[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,459,551,578.44, a slight decrease of 0.38% from ¥2,469,053,947.84 at the end of the previous year[5] - Current liabilities rose to CNY 767,897,890.29, an increase of 17.4% compared to CNY 654,034,226.07 at the start of the year[23] - Total liabilities increased to CNY 1,009,183,586.25 from CNY 977,247,826.66, reflecting a growth of 3.3%[23] - Non-current assets totaled CNY 1,478,713,003.29, up from CNY 1,463,558,529.70, indicating a growth of 1.7%[22] - The company's retained earnings decreased to CNY 600,543,239.78 from CNY 644,581,781.63, a decline of 6.8%[23] Expenses - Research and development expenses increased by 78.90% to ¥16,432,520.06, primarily due to costs associated with vitamin B2 process research and other pharmaceutical product developments[10] - The company reported a significant increase in sales expenses, which rose by 106.17% to ¥9,763,244.33, mainly due to market research and advertising costs[10] - Total operating costs increased to CNY 160,483,094.07, up 19.4% from CNY 134,378,996.03 in the previous year[25] Investments and Financing - Short-term borrowings increased by 36.46% to ¥269,000,000.00, driven by the need for production and operational financing[8] - The net cash flow from financing activities decreased by 65.04% to ¥56,711,572.15, primarily due to a reduction in bank loans obtained during the reporting period[12] - The company plans to establish a joint venture with Jining Yanzhou District Huimin Urban Investment Co., holding 90% of the joint venture, with a registered capital of RMB 520 million[16] - The total price for the restructuring transaction involving four companies is RMB 520 million, with the company bearing 90% of the cost, amounting to RMB 468 million[16] - The company has approved a borrowing limit of RMB 200 million from its controlling shareholder, with a loan term of 3 years at an interest rate of 4.8%[18] - The company plans to engage in financing leasing with a total financing amount of RMB 140 million for production equipment over a 3-year lease term[18] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 30,659[14] - The largest shareholder, Changjiang Industrial Investment Group, holds 24.75% of the shares, totaling 87,592,065 shares[14] - The company’s controlling shareholder had 37,539,103 shares released from restrictions on April 18, 2023[19] Subsidiaries and Corrections - The company has established a wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., to serve as a chemical synthesis base[20] - The company corrected prior accounting errors, impacting the consolidated profit and loss statement for 2022 and 2021, but not affecting the balance sheet or cash flow statement[19] - The company has completed the registration of its wholly-owned subsidiary and obtained the business license from the local authority[20]